Dr Yin Yuan is a clinical haematologist in the Haematology Department at the Royal Melbourne Hospital and Peter MacCallum Cancer Centre and a current PhD student at the Walter and Eliza Hall Institute.
Her research has demonstrated that a new class of drugs called STING agonists have remarkable efficacy in preclinical models of Acute Myeloid Leukaemia (AML), including against high risk subtypes such as TP53 mutated AML.
This work has been presented at national and international meetings, and will form the basis for the development of a phase I clinical trial.